The CEO sale is small relative to his likely total holdings and the company's market cap. Monitor for any material negative news (e.g., FDA setback on aficamten) that could explain the timing, but the dollar amount is too small to warrant a bearish read on its own. The 18 director grants are routine annual equity awards and carry no signal.
Price Chart
Executive Summary
Two insiders at Cytokinetics, including the President & CEO, sold a total of $949K in open-market sales over a one-week window. The CEO's sale of $579K at $77.21 and a director's sale of $370K at $74.08 represent 0.01% of the $9.6B market cap, which is trivial relative to company size. The cluster is overwhelmingly composed of non-cash director grants (18 transactions, $0 value) that are routine compensation events and carry no informational signal. The open-market sales are small and likely liquidity-driven, not indicative of material negative sentiment.
Key Financial Metrics
Key Facts
- President & CEO Robert Blum sold 7,500 shares at $77.21 for $579K on 2026-05-27
- Director B. Lynne Parshall sold 5,000 shares at $74.08 for $370K on 2026-06-01
- Total open-market sales of $949K represent ~0.01% of CYTK's $9.6B market cap
- 18 director grants on 2026-05-27 were non-cash awards (total $0) — routine compensation
- No C-suite insider buying observed in the cluster
- Historical calibration shows prior CYTK reports with score 6-8 had negative average T+5 returns, suggesting the market often disagrees with bearish reads on this name
Financial Impact
Total insider sales of $949K, or ~0.01% of market cap — immaterial
Risk Factors
- CEO selling near $77 could indicate personal diversification rather than bearish view, but any future insider sales at lower prices would be more concerning
- No insider buying to offset the sales — lack of bullish signal from management
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1780354194353 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access